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Abstract
Antibiotics induced acute kidney injury (AKI) risk in critically ill patients is not well known.
This study aimed to evaluate the AKI development and clinical outcomes in critically ill adult
patients treated with vancomycin (VAN) or combined with piperacillin-tazobactam (TZP) or
meropenem (MEM). This was a retrospective study on critically ill adult patients who were
given VAN, TZP or MEM and maintained for at least 48 h. The risk of AKI development and
clinical outcomes were compared using the simple analysis and multivariate logistic regres-
sion. Three hundred forty patients were eligible. The incidence of any AKI was significantly
higher in patients treated with VAN + TZP than those with VAN + MEM or VAN alone (52.7%
vs. 27.7% vs. 25.7%; p < .0001). The adjusted odds of AKI increased 2.43-fold in VAN +
TZP versus VAN, but not different in VAN + MEM versus VAN. However, AKI duration and
recovery rate were not statistically different. In addition, all-cause death within 30 days after
AKI onset was not significantly associated with antibiotic regimens. AKI incidence is higher
in critically ill patients administered with VAN + TZP than those with VAN + MEM or VAN.
However, no obvious evidence was found to prove that antibiotic-induced AKI leads to poor
clinical outcomes.
Introduction
Acute kidney injury (AKI) is defined as a sudden decrease in kidney function involving both
structural damage and loss of function [1]. According to Kidney Disease Improving Global
Outcomes (KDIGO), AKI is defined as an increase in serum creatinine (SCr) level by�0.3
mg/dL within 48 h or by�50% from baseline that is occurring within the first seven days [2].
AKI frequently occurred in 8–22.7% of hospitalised patients, and the incidence was
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approximately 19.0–63.3% in critically ill patients [3–4]. AKI development was associated with
increased hospital stay, mortality, and cost [5]. A study reported that a SCr level of>0.5 mg/
dL was associated with>6.5-fold increase in mortality, an increase in hospital length of stay of
3.5 days, and an increase in average hospital cost>$5,000; therefore, AKI development should
be prevented and controlled [5].
Critically ill patients are commonly given broad-spectrum antibiotics to manage both
gram-positive and gram-negative bacteria [6]. Vancomycin (VAN) is usually combined with a
beta-lactam such as piperacillin-tazobactam (TZP) or meropenem (MEM) [6–7]. VAN-associ-
ated renal toxicity has been reported, and AKI risk may be higher in those who received com-
bination therapy with antipseudomonal beta-lactam antibiotics, such as TZP and MEM and
some studies supported them [8–13]. Luther et al. reported that AKI incidence is higher in
patients receiving VAN + TZP than those receiving VAN + cefepime (FEP)/carbapenem in a
systematic review and meta-analysis [9]. However, FEP and carbapenems were grouped
together among critically ill patients, making individual comparisons difficult in this study. A
comparative study conducted on 10,236 patients in general wards reported that VAN + TZP
has significantly higher nephrotoxicity than VAN + MEM [12]. On the other hand, compari-
sons on VAN and antipseudomonal beta-lactam especially MEM-induced AKI development
for use more than 48 hours were limited, in addition, previous researches have been mostly
restricted to compare concomitant clinical prognosis such as recovery rate and mortality in
intensive care unit (ICU) patients [14,15]. Therefore, comparison studies of individual antibi-
otics combined with VAN in patients admitted to ICU were restricted until now.
This study evaluated the difference in AKI development such as incidence, duration and
recovery, and concomitant clinical prognosis according to the antibiotic regimens adminis-
tered in patients with VAN monotherapy or combination of VAN + TZP or MEM.
Materials and methods
Ethics
The study protocol was approved by the Severance Hospital Institutional Review Board
(approval number: 4-2018-0715). Informed consent from patients was waived because this ret-
rospective study did not exceed the minimal risk.
Study design and population
This retrospective cohort study included critically ill adult patients (age�18 years) who were
admitted to any ICUs, including the surgical, medical, cancer, or coronary departments of Sev-
erance Hospital, a 3,362-bed tertiary academic hospital in Seoul, South Korea, between January
2015, and December 2017.
The study included all patients who were not administered VAN, TZP, FEP, or MEM
within 72 h before the ICU admission; started and maintained the treatment for at least 48 h
after ICU admission; and had a starting interval between VAN and beta-lactams of less than
48 h as per hospital protocol. The antibiotic doses were adjusted for the patient’s kidney func-
tion based on the product information. The study excluded patients with previous severe renal
disease, such as end-stage renal dysfunction, chronic kidney disease stage IV, kidney trans-
plantation (ICD-10 code: N18.5, I12.0, N18.4, Z94.0, T86.1), and acute kidney injury (N17) 48
h before ICU admission. Patients with a baseline glomerular filtration rate of 30 mL/min/1.73
m2 or more according to the CKD-EPI creatinine equation were included, and those without
baseline SCr data were also excluded.
Antibiotics induced acute kidney injury and clinical prognosis in ICU
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Clinical outcomes
Main outcomes were the AKI development, onset time, duration of AKI. AKI was defined
based on KDIGO criteria as increased SCr level of 0.3 mg/dL within 48 h or�1.5 times than
the baseline values [2]. AKI stage 2 was defined as 2.0–2.9 times higher than the baseline; stage
3, 3.0 times higher than the baseline or increased SCr level of�4.0 mg/dL. The development of
any AKI was observed during maximum 15 days of therapy or within 72 hours after the com-
pletion of therapy. Recovery was defined as SCr level restoration of<1.5 times the baseline.
AKI duration was defined as days from onset to recovery.
In addition, concomitant clinical outcomes including recovery rate, all-cause death, length
of hospital stay, and the need of dialysis were evaluated within 30 days after the AKI onset.
Data collection
Clinical data, including demographics, comorbidities from 30 days before to 7 days after anti-
biotic treatment, SCr concentrations, concurrent nephrotoxic drugs during antibiotic treat-
ment, and information on cultured bacteria from 30 days before to 7 days after antibiotic
treatment, were extracted from the electronic medical records using the Clinical Data Retrieval
System of Severance Hospital. The SCr concentration recorded as<0.2 mg/dL were substi-
tuted to be 0.2 mg/dL. Acute Physiology and Chronic Health Evaluation II (APACHE II)
scores were collected within 24 h of ICU admission. Concurrent nephrotoxic drugs were cate-
gorised as follows: IV contrast, calcineurin inhibitors (cyclosporine and tacrolimus), nonste-
roidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists, vasopressors (dobutamine, dopamine, epinephrine, and norepineph-
rine), diuretics (acetazolamide, amiloride, furosemide, hydrochlorothiazide, and spironolac-
tone), and alkylating agents (cyclophosphamide, cisplatin, and ifosfamide). Baseline SCr
concentrations were collected on the first day of antibiotic administration. If the SCr data were
not recorded at the start of antibiotic administration, data before and after 24 h of antibiotic
administration were used. The length of hospital stay was calculated from the initiation of anti-
biotic treatment until hospital discharge or all-cause death.
Statistical analysis
All analyses were conducted with SAS ver. 9.4 (SAS Institute, Cary, NC, USA). Figures were
drawn using the GraphPad Prism version 6.07 for Windows (GraphPad Software, La Jolla, CA,
USA). The number of patients in the VAN + FEP group is too small to use statistically; there-
fore, only the other three groups (VAN alone, VAN + TZP, and VAN + MEM) were statisti-
cally analysed.
Continuous data among the three groups were compared using ANOVA or the Kruskal–
Wallis test. Discrete data were compared using the chi-squared or Fisher’s exact test. Kaplan–
Meier analysis and log-rank test were performed to compare AKI developmental probability.
A p-value of<0.05 was considered statistically significant, which was adjusted using the Bon-
ferroni correction.
Multivariate logistic regression was performed to evaluate effectiveness of variables associ-
ated with AKI development. Effective variable candidates were selected based on the p-value of
<0.1 using simple analysis between those with and without development, and candidates were
selected as follows: APACHE II score, antibiotics treatment group, sepsis and pneumonia
among comorbidities, cardiogenic and septic shock, contrast and diuretics, and epinephrine,
norepinephrine, dobutamine, and dopamine vasopressor among the concurrent nephrotoxic
drugs. Demographic data, such as age, sex, and weight, were also included. Suitable variables
were chosen using the LOGISTIC procedure and the stepwise selection using the SAS
Antibiotics induced acute kidney injury and clinical prognosis in ICU
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software. The probability model was the AKI group, and the goodness-of-fit of the multivariate
logistic model was evaluated using the Hosmer–Lemeshow test [16].
Results
Patient characteristics
Table 1 shows the patient characteristics among those treated with VAN, VAN + TZP, and
VAN + MEM. Among the 970 screened patients, 340 were eligible consisting of 183 in VAN,
74 in VAN + TZP, 83 in VAN + MEM. The median duration of antibiotic therapy was 7.0
days (interquartile range [IQR] 8.0).
Table 1 shows the patient characteristics among those treated with VAN, VAN + TZP, and
VAN + MEM. The duration of antibiotic therapy and mean VAN daily dose among the three
groups did not show significant differences. The APACHE II score was significantly lower in
patients treated with VAN, which means that patients with more severe disease tended to
receive VAN + TZP or VAN + MEM combination therapy. In addition, the combination of
VAN + MEM therapy had been used for more severe infections than VAN or VAN + TZP,
with higher proportion of sepsis, septic shock, and positive cultures, especially Acinetobacter,
Klebsiella, and Escherichia. In addition, patients treated with VAN + MEM tended to stay lon-
ger in the hospital than VAN or VAN + TZP. Vasopressor was used in 220 ICU (62.9%)
patients, particularly norepinephrine in 209 (59.7%) and epinephrine in 75 (21.4%) among the
total participants. The vasopressor treatment was lowest in VAN (VAN vs. VAN + TZP, 49.2%
vs. 83.8%, p< .0001; VAN + TZP vs. VAN + MEM, 83.8% vs. 73.5%, p = 0.118).
Comparison of AKI development and clinical outcomes
The AKI development defined by KDIGO in 114 patients (32.6%) consisted of 47 in VAN, 39
in VAN + TZP, 23 in VAN + MEM as presented in Table 2. In multiple comparisons to VAN,
the AKI incidence was significantly higher in VAN + TZP (p< .0001) and similar in VAN
+ MEM (p = 0.728). The AKI stage 2 incidence was statistically higher in VAN + TZP than
that in VAN + MEM or VAN alone (21.6% vs. 9.6% vs. 6.6%; p< .001). AKI stage 3 highly
occurred in patients treated with VAN + TZP than those with VAN or VAN + MEM, but not
statistically different (8.1% vs. 5.0% vs. 2.4%; p = 0.072). Kaplan–Meier analysis revealed a
higher cumulative incidence of AKI in patients treated with VAN + TZP than those with VAN
or VAN + MEM (Fig 1). The curve of AKI developmental probability was similar between
VAN and VAN + MEM (p = 0.971), but not between VAN + TZP and VAN or VAN + MEM
(p< .0001).
The median days of onset time to AKI were 4.0 (IQR 5.0) days in all patients, and the differ-
ence was not shown (VAN vs. VAN + TZP vs. VAN + MEM; 4.0 days vs. 4.0 days vs. 5.0 days;
p = 0.911). The AKI onset persisted even after seven days and increased until approximately 10
days after initiating antibiotic therapy (Fig 1). The time of AKI incidence reaching to 50% was
8.0 days (95% CI 5.0–9.0) in VAN + TZP.
A total of 78 patients (71.6%) recovered from AKI, and the highest recovery rate was
achieved with VAN + TZP (84.6%), but it was not statistically significant (p = 0.071) (Table 3).
The AKI duration in each treatment group was not statistically different in both any AKI
(p = 0.821) and AKI stage 2 or 3 (p = 0.538). The median duration of any AKI was 2.0 days
(IQR 5.0) in the three treatment groups, but AKI duration in stage 2 or 3 was slightly longer
(median 6.0 days, IQR 8.0).
Table 3 shows the evaluation of concomitant clinical outcomes according to the antibiotic
treatment groups. All-cause death within 30 days after AKI onset was also similar among the
three groups (25.5% in VAN, 23.1% in VAN + TZP, and 39.1% in VAN + MEM; p = 0.271).
Antibiotics induced acute kidney injury and clinical prognosis in ICU
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Table 1. Patient characteristics according to antibiotics group.
Variables VancomycinV Vancomycin + Piperacillin/
tazobactamVP
Vancomycin
+ MeropenemVM
p-value Post hoc
Sample size, n (%) 183 74 83 -
Males, n (%) 121 (66.1) 55 (74.3) 50 (60.2) 0.174
Age, years, mean ± SD 59.1 ± 16.4 60.1 ± 17.6 58.9 ± 15.9 0.884
Weight, kg, mean ± SD 63.5 ± 13.0 65.3 ± 12.9 59.7 ± 11.5 0.015 V,
VP > VM
BMIa, kg/m2, mean ± SD 23.0 ± 4.5 23.6 ± 4.0 22.6 ± 4.1 0.334
APACHE II score, mean ± SD 21.0 ± 8.5 24.1 ± 8.2 24.5 ± 9.0 0.003 VM,
VP > V
Serum creatinine, mg/dL, median (IQR) 0.7 (0.4) 0.9 (0.4) 0.7 (0.5) 0.005 VP > V,
VM
eGFR, mL/min/1.73 m2, median (IQR) 97.8 (36.3) 86.8 (31.3) 95.8 (40.7) 0.017 V > VP
Vancomycin daily dose
g/day, mean ± SD 1.9 ± 0.4 1.7 ± 0.6 1.8 ± 0.5 0.088
mg/kg/day, mean ± SD 30.6 ± 10.2 27.3 ± 10.8 30.7 ± 11.1 0.060
Beta-lactam daily dose, g/day, mean ± SD - 14.0 ± 3.3 2.6 ± 0.6 -
Interval of co-administration�24 h, n (%) - 68 (91.9) 75 (90.4) 0.737
Duration of Therapy, day, median (IQR) 8.0 (9.0) 6.5 (5.0) 8.0 (9.0) 0.136
Length of hospital stay after start of antibiotics, day,
median (IQR)
18.0 (26.0) 20.5 (34.5) 32.0 (45.0) 0.001 VM > V,
VP
Comorbidities, n (%)
Hypertension 85 (46.5) 31 (41.9) 31 (37.4) 0.369
Diabetes mellitus 45 (24.6) 22 (29.7) 14 (16.9) 0.158
Heart failure 18 (9.8) 16 (21.6) 15 (18.1) 0.028 VP > V
Sepsis 20 (10.9) 11 (14.9) 22 (26.5) 0.005 VM > V,
VP
Pneumonia 15 (8.2) 11 (14.9) 13 (15.7) 0.122
Shock, n (%)
Cardiogenic 12 (6.6) 17 (23.0) 3 (3.6) <
.0001
VP > V,
VM
Septic 14 (7.7) 9 (12.2) 18 (21.7) 0.005 VM > V
Hypovolemic 1 (0.6) 1 (1.4) 3 (3.6) 0.125
Concurrent nephrotoxic drugs, n (%)
Contrast 31 (16.9) 28 (37.8)) 10 (12.1)) <
.0001
VP > V,
VM
Calcineurin inhibitor 7 (3.8) 2 (2.7) 10 (12.1) 0.020 VM > V
NSAIDb 79 (43.2) 37 (50.0) 37 (44.6) 0.606
ACE inhibitorc 15 (8.2) 5 (6.8) 5 (6.0) 0.801
ARBd 20 (10.9) 8 (10.8) 1 (1.2) 0.023 V,
VP > VM
Vasopressor
Epinephrine 21 (11.5) 20 (27.0) 15 (18.1) 0.009 VP > V,
VM
Norepinephrine 73 (39.9) 56 (75.7) 56 (67.5) <
.0001
VP,
VM > V
Dobutamine 10 (5.5) 6 (8.1) 7 (8.4) 0.586
Dopamine 1 (0.6) 9 (12.2) 2 (2.4) <
.0001
VP > V,
VM
Diuretics 125 (68.3) 58 (78.4) 65 (78.3) 0.116
Alkylating agent 1 (0.6) 1 (1.4) 0 (0) 0.448
(Continued)
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The length of hospital stay after AKI in patients treated with VAN + MEM was longer than
those receiving other treatments (15.0 days in VAN, 26.0 days in VAN + TZP, 36.0 days in
VAN + MEM; p = 0.038). Few patients required dialysis (n = 7, 6.4%), which was consistent
among the three treatment groups (p = 0.886). In AKI stage 2 or 3, all outcomes were not dif-
ferent among treatment groups.
Risk factor analysis
S1 Table shows a comparison of all variables, using simple analysis between the AKI and no-
AKI group, to determine variables that affect the AKI development. Effective variables were
Table 1. (Continued)
Variables VancomycinV Vancomycin + Piperacillin/
tazobactamVP
Vancomycin
+ MeropenemVM
p-value Post hoc
Amphotericin 7 (3.8) 1 (1.4) 9 (10.8) 0.019 VM > V,
VP
Aminoglycoside 3 (1.6) 1 (1.4) 10 (12.1) 0.001
Rifampicin 4 (2.2) 2 (2.7) 0 (0) 0.417
Positive cultures, n (%)
Pseudomonas 16 (8.7) 7 (9.5) 11 (13.3) 0.517
Acinetobacter 24 (13.1) 4 (5.4) 25 (30.1) <
.0001
VM > V,
VP
Klebsiella 13 (7.1) 9 (12.2) 23 (27.7) <
.0001
VM > V,
VP
Stenotrophomonas 7 (3.8) 3 (4.1) 6 (7.2) 0.455
Enterobacter 9 (4.9) 4 (5.4) 7 (8.4) 0.528
Escherichia 17 (9.3) 1 (1.4) 13 (15.7) 0.008 VM,
V > VP
The bold values indicate statistically significant difference (p-value < 0.05).
aBMI = Body mass index
bNSAID = Non-steroidal anti-inflammatory drugs
cACE inhibitor = Angiotensin-converting-enzyme inhibitor
dARB = Angiotensin II receptor blocker
The data were presented in mean ± standard deviation (SD) when the one-way analysis of variance (ANOVA) test was used according to their distribution of
continuous variables; otherwise, median (interquartile range, IQR) was presented in Kruskal–Wallis test. However, the chi-square test was performed, or Fisher’s
expected test was performed if the expected frequency was <5 for categorical variables. A post hoc test was performed using the adjusted Bonferroni correction.
https://doi.org/10.1371/journal.pone.0217908.t001
Table 2. Comparison between acute kidney injury development according to treatment group.
Outcomes VancomycinV Vancomycin + Piperacillin/tazo-bactamVP Vancomycin + MeropenemVM p-value Post hoc
Incidence of AKI, n (%)
Any AKI 47 (25.7) 39 (52.7) 23 (27.7) < .0001 VP > V, VM
AKI stage 1 26 (14.2) 17 (23.0) 13 (15.7) 0.028 VP > V
AKI stage 2 12 (6.6) 16 (21.6) 8 (9.6) < .001 VP > V, VM
AKI stage 3 9 (5.0) 6 (8.1) 2 (2.4) 0.072
Onset time to any AKI, days, median (IQR) 4.0 (5.0) 4.0 (5.0) 5.0 (7.0) 0.911
Duration of AKI, days (IQR)
Any AKI 2.0 (6.0) 3.0 (4.0) 2.0 (5.0) 0.821
Stage 2 or 3 7.5 (11.5) 5.0 (6.0) 2.0 (8.0) 0.538
The bold values indicate statistically significant difference (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0217908.t002
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the APACHE II scores, antibiotic treatment groups, sepsis status, and use of norepinephrine.
The final model of the multivariate logistic regression is shown in Table 4. The area under the
curve was 0.741, and the p-value of Hosmer–Lemeshow test was 0.659, which means this
model fitted well. Risk factors that significantly affected the AKI development were sex, use of
combination therapy of VAN plus TZP, sepsis, and use of norepinephrine (Table 4). The odds
of AKI in VAN + TZP were significantly higher than VAN, but not between VAN + MEM and
Fig 1. AKI development probability graph according to the survival analysis and log-rank test. Dotted red line
marked indicates vancomycin monotherapy; continuous blue line indicates vancomycin plus piperacillin-tazobactam
combination therapy; continuous black line represents vancomycin plus meropenem combination therapy; censored
events were marked with crosses.
https://doi.org/10.1371/journal.pone.0217908.g001
Table 3. Evaluation of clinical outcomes according to treatment group.
Outcomes Vancomycin Vancomycin + Piperacillin/tazobactam Vancomycin + Meropenem p-value
Recovery rate of AKI, n (%)
Any AKI 31 (66.0) 33 (84.6) 14 (60.9) 0.071
AKI stage 2 or 3 12 (57.1) 17 (77.3) 7 (70.0) 0.563
Length of hospital stay after AKI onset, median (IQR)
Any AKI 15.0 (26.0) 26.0 (48.5) 36.0 (81.0) 0.038�
AKI stage 2 or 3 33.0 (55.0) 21.5 (45.0) 92.0 (132.0) 0.206
Dialysis within 30 days after AKI onset
Any AKI 3 (6.4) 2 (5.1) 2 (8.7) 0.886
AKI stage 2 or 3 1 (4.8) 1 (4.6) 1 (10.0) 0.793
All-cause death within 30 days after AKI onset, n (%)
Any AKI 12 (25.5) 9 (23.1) 9 (39.1) 0.362
AKI stage 2 or 3 7 (33.3) 6 (27.3) 4 (40.0) 0.765
The bold values indicate statistically significant difference (p-value < 0.05).
�The result of Post hoc: Vancomycin + Meropenem > Vancomycin
https://doi.org/10.1371/journal.pone.0217908.t003
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VAN. The APACHE II score was determined as an effective variable with p-value of less than
0.05, but was not as a powerful predictor of AKI. Norepinephrine use and sepsis increased the
probability of AKI development. In addition, the risk of AKI development was higher in
women than in men.
Discussion
In our study, the VAN + TZP had significantly higher AKI incidence than VAN or VAN
+ MEM (52.7% vs. 25.7% vs. 27.7%; p< .0001) in critically ill patients. In the multivariate
logistic regression, including risk factor variables, the VAN + TZP group was shown to have
higher odds than VAN or VAN + MEM. The median onset time and duration of AKI were
also not different among all treatment groups. By contrast, concomitant outcomes within 30
days after AKI such as recovery rate, all-cause death, need of dialysis was also similar among
all groups. The length of hospital stay was the longest in the VAN + MEM group after AKI, but
this was shown also at the baseline. AKI was the most common in VAN + TZP, but it did not
decisively influence the length of hospital stay.
This result of AKI incidence is fairly consistent with the previous reports on antibiotic
nephrotoxicity. A large-scale retrospective study comparing VAN + TZP and VAN + MEM
found that the former was associated with higher nephrotoxicity than the latter in non-criti-
cally ill patients [12]. In a sub-analysis among critically ill patients from a meta-analysis, Luther
et al reported that VAN + TZP group showed higher nephrotoxicity than VAN monotherapy
(OR = 9.62, 95% CI 4.48–20.68), but not statistically different compared to VAN + FEP/carba-
penem (OR = 1.43; 95% CI 0.83–2.47) [9]. However, FEP and carbapenem plus VAN group
was analysed as the same group and individual risk could not be shown and sample size of
VAN + carbapenem was only 13 among 158 patients of VAN + FEP/carbapenem group.
Moreover, they did not compare clinical outcomes among treatment groups followed by AKI.
This is the first report that risk comparison of AKI and concomitant clinical outcomes by
selection of TZP or MEM in critically ill patients.
We found that VAN + TZP significantly increased any AKI incidence including stage 2 or 3
after being administered for more than 48 h (median duration of treatment = 7.0 days). One
recent paper reported that types of antipseudomonal beta-lactams used as a brief empiric ther-
apy for less than 72 h with a median of 1.5 days did not affect the development of AKI stage 2
Table 4. Effective factors for development of AKI.
Variables Univariate OR 95% CI Multivariate OR 95% CI
Treatment antibiotics
Vancomycin + Piperacillin/tazobactam (ref. Vancomycin) 3.22 1.83 5.67 2.52 1.35 4.71
Vancomycin + Meropenem (ref. Vancomycin) 1.11 0.62 1.99 0.73 0.38 1.42
Demographics
Female (ref. male) 1.47 0.91 2.36 2.13 1.21 3.72
Age 1.01 1.00 1.02 1.01 0.99 1.02
Weight 1.01 1.00 1.03 1.02 1.00 1.04
APACHE II score 1.06 1.03 1.09 1.04 1.01 1.08
With sepsis (ref. without sepsis) 2.37 1.30 4.30 2.32 1.19 4.52
Used norepinephrine (ref. unused norepinephrine) 3.31 2.01 5.44 2.03 1.15 3.59
OR = Odds ratio
CI = Confidence interval
The univariate OR was calculated according to the univariate logistic regression, and the multivariate OR was calculated according to the multivariate logistic regression.
https://doi.org/10.1371/journal.pone.0217908.t004
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or 3 in ICU patients [15]. Although the duration of antibiotic treatment as empiric therapy is
gradually decreasing, a multicentre ICU study reported that 50% of patients receiving empiric
antibiotic therapy continued treatment for at least 72 h, and the probability of ventilator-asso-
ciated pneumonia was lower with prolonged empiric antibiotic therapy (45.1% vs. 59.5%;
p = 0.03) [6, 17]. In addition, the median duration of the unchanged empiric course was 5.5
days in an observational cohort study of empiric antibiotic therapy in six hospitals, and the
rate of regimen changes within five days after initiating the empiric antibiotic therapy was
reported to be less than one in three [18]. Therefore, this is a meaningful basis for an actual
clinical situation by comparing the AKI incidence according to the antibiotic use for more
than 48 h. To our knowledge, this is the first study that evaluated the AKI risks between VAN
monotherapy and VAN plus MEM or TZP used more than 48 h in ICU patients.
The current study found that AKI incidence differs depending on antibiotic regimens, but
did not have a decisive influence on poor clinical outcomes, such as the recovery rate and all-
cause death and need of dialysis within 30 days after AKI onset (Table 3). This was also shown
in the sub-analysis with AKI stage 2 or 3. In a previous study on non-ICU patients, AKI inci-
dence was higher in the VAN + TZP group than the others, but did not directly result in poor
clinical outcomes [11]. Although VAN’s nephrotoxic mechanism is presumably due to oxida-
tive stress, that of TZP remains unclear [19, 20]. One study of critically ill patients reported
that the renal filtration rate recovery was more delayed in TZP than MEM-treated patients
while being exposed to the antibiotics (1.0 mL/min/1.73 m2/24 h vs. 2.9 mL/min/1.73 m2/24 h)
[21]. But the renal filtration rate was recovered after discontinuing TZP (2.7 mL/min/1.73 m2/
24 h), and they had shown that renal toxicity due to TZP was at least partially reversible [21].
We thought that renal function was partially restored by dose reduction or discontinuation of
TZP, and then VAN + TZP-induced AKI did not primarily affect the clinical outcomes.
Critically ill patients are at high risk of developing AKI due to the complexity of concomi-
tant nephrotoxic drugs, comorbidity, hemodynamic instability, or others [14, 22]. In this study
risk factors that affect AKI development were female sex, sepsis, use of norepinephrine, and
type of beta-lactam antibiotics (Table 4). This finding is consistent with previous studies, espe-
cially regarding sex and sepsis [23–27]. Women were estimated to have fewer glomeruli and
nephrons than men, which may lead to a lower renal functional reserve [28]. Sepsis-induced
AKI has been explained based on hypoperfusion, microvascular dysfunction, inflammation,
and cellular response to inflammatory insults [27]. Contrary to that of the previous studies
which suggested that most systemic hemodynamic parameters were not associated with AKI
development, norepinephrine was one of risk factors in our study [29]. We suspect that hemo-
dynamic status which needs norepinephrine use might have caused AKI in critically ill
patients.
The percentage of sepsis in the VAN + MEM group was significantly higher than VAN or
VAN + TZP (26.5% vs. 14.9% vs. 10.9%; p = 0.005), and the proportion of cultured bacteria
with low susceptibility to antibiotics, such as Acinetobacter, Klebsiella, and Escherichia spp.,
was also high in VAN + MEM [30]. The length of hospital stay after antibiotic administration
was also the longest in VAN + MEM, regardless of AKI incidence. According to the Sanford
Guide to Antimicrobial Therapy 2018, the primary treatment option was MEM, not TZP, in
systemic infection of Acinetobacter baumannii, Klebsiella pneumonia or Escherichia spp., and
Pseudomonas aeruginosa [7]. Previous studies indicated severe infection frequently causes fatal
conditions, and mortality was 27.4% even with adequate antibiotic administration [31, 32].
Thus, MEM tended to be used in severe infections compared to TZP, so treatment selection
bias could be observed. However, even after controlling bias by logistic regression, VAN
+ TZP had more risk than VAN + MEM to cause AKI (Table 4). According to these data, we
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could infer that the choice of beta-lactam antibiotics as well as sepsis has a large impact on AKI
regardless of other factors in ICU patients.
This study has some limitations. We defined the incidence of AKI based solely on the
changed in SCr level because not all patients were measured the level of urine output, so the
actual incidence of AKI may have been underestimated [33]. Although we tried to remove
confounding factors and selection bias through multivariate logistic regression, the inherent
limitation of a retrospective cohort research that various confounders could not be totally
removed.
To our knowledge, this was the first study to assess the AKI incidence due to antibiotic regi-
mens, such as VAN alone, VAN + TZP, and VAN + MEM in the ICU, which was associated
with the comparison of clinical outcomes. This study provides new insights that the AKI
occurred with VAN + TZP than those with VAN or VAN + MEM when antibiotics are used
for longer than 48 h. This finding significantly indicated that antibiotics should be chosen in
accordance with the patients’ clinical situation, rather than focusing on drug effect of AKI
development in critically ill patients. In addition, kidney function recovery is higher in patients
treated with VAN + TZP than those with VAN + MEM or VAN monotherapy in real clinical
situations, which may be the basis of supporting the reversible nephrotoxicity of TZP.
Conclusions
In conclusion, the AKI incidence in patients treated with VAN + TZP is higher than those
treated with VAN monotherapy or VAN + MEM; however, this does not seem to have a deci-
sive influence on clinical outcomes. AKI development and clinical outcomes of critically ill
patients are presumed to be influenced not only by the antibiotic regimen, but also by infection
severity, such as sepsis or sex. This study is expected to contribute to a deeper understanding
of antibiotic nephrotoxicity and to provide meaningful results that will guide prescribing
appropriate antibiotics to critically ill patients who might develop AKI.
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